(IMNM) Immunome - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.471m USD | Total Return: 267% in 12m

Cancer Therapies, Drug Candidates, Clinical Trials
Total Rating 47
Safety 74
Buy Signal -0.02
Biotechnology
Industry Rotation: +3.7
Market Cap: 2.47B
Avg Turnover: 23.6M USD
ATR: 5.77%
Peers RS (IBD): 80.3
Risk 5d forecast
Volatility75.8%
Rel. Tail Risk-10.3%
Reward TTM
Sharpe Ratio2.05
Alpha216.07
Character TTM
Beta1.276
Beta Downside1.375
Drawdowns 3y
Max DD79.66%
CAGR/Max DD0.76
EPS (Earnings per Share) EPS (Earnings per Share) of IMNM over the last years for every Quarter: "2021-03": -0.37, "2021-06": -0.46, "2021-09": -0.65, "2021-12": -0.68, "2022-03": -0.96, "2022-06": -0.74, "2022-09": -0.75, "2022-12": -0.64, "2023-03": -0.35, "2023-06": -0.46, "2023-09": -0.36, "2023-12": -4.22, "2024-03": -2.51, "2024-06": -0.49, "2024-09": -0.78, "2024-12": -1.11, "2025-03": -0.52, "2025-06": -0.5, "2025-09": -0.65, "2025-12": -0.76, "2026-03": 0,
EPS CAGR: 5.19%
EPS Trend: 14.7%
Last SUE: 0.90
Qual. Beats: 1
Revenue Revenue of IMNM over the last years for every Quarter: 2021-03: 0, 2021-06: 0.5, 2021-09: 0.006, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 2.364, 2023-06: 4.263, 2023-09: 3.565, 2023-12: 3.826, 2024-03: 1.029, 2024-06: 2.364, 2024-09: 2.91, 2024-12: 2.738, 2025-03: 2.926, 2025-06: 4.015, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: 27.2%
Last SUE: -0.46
Qual. Beats: 0

Warnings

Share dilution 39.3% YoY - potential capital distress

Interest Coverage Ratio -219.8 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: IMNM Immunome

Immunome, Inc. (NASDAQ: IMNM) is a clinical-stage biotechnology company developing cancer therapies.

The companys lead candidate, Varegacestat, a gamma secretase inhibitor, is in Phase 3 trials for desmoid tumors. Desmoid tumors are rare, non-cancerous growths that can be locally aggressive.

Immunome also has an antibody-drug conjugate (ADC), IM-1021, in Phase 1 trials. ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer, delivering cytotoxic agents directly to cancer cells.

Preclinical assets include a radioligand therapy, IM-3050, and additional solid tumor ADC candidates.

Immunome, Inc. was founded in 2006 and is headquartered in Bothell, Washington. Further research on platforms like ValueRay can provide deeper insights into IMNMs pipeline and financial health.

Headlines to Watch Out For
  • Varegacestat Phase 3 trial results impact future revenue
  • IM-1021 Phase 1 trial progress drives investor sentiment
  • Development of new ADC candidates expands future pipeline
  • Regulatory approvals for therapies determine market access
  • Clinical trial costs significantly affect company profitability
Piotroski VR‑10 (Strict) 0.0
Net Income: -212.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.29 > 0.02 and ΔFCF/TA 19.84 > 1.0
NWC/Revenue: 8.87k% < 20% (prev 1.85k%; Δ 7.02k% < -1%)
CFO/TA -0.28 > 3% & CFO -190.9m > Net Income -212.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 14.69 > 1.5 & < 3
Outstanding Shares: last quarter (87.4m) vs 12m ago 39.31% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 1.50% > 50% (prev 3.76%; Δ -2.26% > 0%)
Interest Coverage Ratio: -219.8 > 6 (EBITDA TTM -208.6m / Interest Expense TTM 962k)
Altman Z'' -15.00
A: 0.90 (Total Current Assets 660.8m - Total Current Liabilities 45.0m) / Total Assets 683.2m
B: -1.07 (Retained Earnings -728.2m / Total Assets 683.2m)
C: -0.46 (EBIT TTM -211.4m / Avg Total Assets 461.7m)
D: -14.91 (Book Value of Equity -728.2m / Total Liabilities 48.8m)
Altman-Z'' Score: -16.29 = D
What is the price of IMNM shares? As of April 08, 2026, the stock is trading at USD 21.58 with a total of 1,483,139 shares traded.
Over the past week, the price has changed by -1.33%, over one month by +1.17%, over three months by +8.01% and over the past year by +267.01%.
Is IMNM a buy, sell or hold? Immunome has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy IMNM.
  • StrongBuy: 7
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the IMNM price?
Analysts Target Price 35.5 64.7%
Immunome (IMNM) - Fundamental Data Overview as of 06 April 2026
P/S = 355.976
P/B = 3.8951
Revenue TTM = 6.94m USD
EBIT TTM = -211.4m USD
EBITDA TTM = -208.6m USD
Long Term Debt = 3.85m USD (from capitalLeaseObligations, last quarter)
 Short Term Debt = unknown (none)
 Debt = 3.85m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -649.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.82b USD (2.47b + Debt 3.85m - CCE 653.5m)
Interest Coverage Ratio = -219.8 (Ebit TTM -211.4m / Interest Expense TTM 962k)
EV/FCF = -9.08x (Enterprise Value 1.82b / FCF TTM -200.6m)
FCF Yield = -11.01% (FCF TTM -200.6m / Enterprise Value 1.82b)
 FCF Margin = -2.89k% (FCF TTM -200.6m / Revenue TTM 6.94m)
 Net Margin = -3.06k% (Net Income TTM -212.4m / Revenue TTM 6.94m)
 Gross Margin = unknown ((Revenue TTM 6.94m - Cost of Revenue TTM 51.4m) / Revenue TTM)
 Tobins Q-Ratio = 2.67 (Enterprise Value 1.82b / Total Assets 683.2m)
Interest Expense / Debt = 24.95% (Interest Expense 962k / Debt 3.85m)
Taxrate = 21.0% (US default 21%)
NOPAT = -167.0m (EBIT -211.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.69 (Total Current Assets 660.8m / Total Current Liabilities 45.0m)
Debt / Equity = 0.01 (Debt 3.85m / totalStockholderEquity, last quarter 634.3m)
 Debt / EBITDA = 3.11 (negative EBITDA) (Net Debt -649.6m / EBITDA -208.6m)
 Debt / FCF = 3.24 (negative FCF - burning cash) (Net Debt -649.6m / FCF TTM -200.6m)
 Total Stockholder Equity = 368.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.00% (Net Income -212.4m / Total Assets 683.2m)
RoE = -57.61% (Net Income TTM -212.4m / Total Stockholder Equity 368.7m)
RoCE = -56.76% (EBIT -211.4m / Capital Employed (Equity 368.7m + L.T.Debt 3.85m))
 RoIC = -45.31% (negative operating profit) (NOPAT -167.0m / Invested Capital 368.7m)
 WACC = 10.48% (E(2.47b)/V(2.47b) * Re(10.47%) + D(3.85m)/V(2.47b) * Rd(24.95%) * (1-Tc(0.21)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 99.49%
 [DCF] Fair Price = unknown (Cash Flow -200.6m)
 EPS Correlation: 14.75 | EPS CAGR: 5.19% | SUE: 0.90 | # QB: 1
Revenue Correlation: 27.16 | Revenue CAGR: 0.0% | SUE: -0.46 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.58 | Chg7d=+0.033 | Chg30d=+0.007 | Revisions Net=+4 | Analysts=12
EPS current Year (2026-12-31): EPS=-2.37 | Chg7d=+0.112 | Chg30d=+0.087 | Revisions Net=+4 | Growth EPS=+2.4% | Growth Revenue=-36.0%
EPS next Year (2027-12-31): EPS=-2.11 | Chg7d=-0.025 | Chg30d=-0.019 | Revisions Net=-1 | Growth EPS=+10.8% | Growth Revenue=+1752.3%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle